ReviewJournal of drug delivery science and technology2021
Technological evolution of cyclodextrins in the pharmaceutical field.
Review in Journal of drug delivery science and technology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Effects of 2-Hydroxypropyl-β-Cyclodextrin on the Antioxidant Efficiency of Some Gallic Acid Derivatives in Soybean Oil-in-Water Emulsions.Antioxidants (Basel, Switzerland) · 2025Article
- Nano-Spray-Drying of Cyclodextrin/Ibuprofen Complexes with Aerosolization-Enhancing Additives for Pulmonary Drug Delivery.International journal of molecular sciences · 2025Article
- New Antioxidant Triphenol-Derived Hydrazide-Hydrazone Thiazole: Formation and Analysis of Inclusion Complex with β-CD Using Experimental and Computational Approaches.Molecules (Basel, Switzerland) · 2025Article
- Cyclodextrins: Enhancing Drug Delivery, Solubility and Bioavailability for Modern Therapeutics.Pharmaceutics · 2025Review
- Cyclodextrins and their potential applications for delivering vitamins, iron, and iodine for improving micronutrient status.Drug delivery and translational research · 2025Review
- Cyclodextrin Complexes for the Treatment of Chagas Disease: A Literature Review.International journal of molecular sciences · 2024Review
- A Review of Machine Learning and QSAR/QSPR Predictions for Complexes of Organic Molecules with Cyclodextrins.Molecules (Basel, Switzerland) · 2024Review
- The development of an innovative method to improve the dissolution performance of rivaroxaban.Heliyon · 2024Article
- Carrier Systems for Advanced Drug Delivery: Improving Drug Solubility/Bioavailability and Administration Routes.Pharmaceutics · 2024Review
- Easy and Effective Method for α-CD:NInternational journal of molecular sciences · 2024Article
- On Interactions of Sulfamerazine with Cyclodextrins from Coupled Diffusometry and Toxicity Tests.Biomolecules · 2024Article
- Drug complexes: Perspective from Academic Research and Pharmaceutical Market.Pharmaceutical research · 2023Review
- Characterization of Thymoquinone-Sulfobutylether-β-Cyclodextrin Inclusion Complex for Anticancer Applications.Molecules (Basel, Switzerland) · 2023Article
- Molecular Mind Games: The Medicinal Action of Cyclodextrins in Neurodegenerative Diseases.Biomolecules · 2023Review
- Hyaluronidase-trigger nanocarriers for targeted delivery of anti-liver cancer compound.RSC advances · 2023Article
- β-cyclodextrin dendritic derivatives as permeation mediators to enhance theRSC advances · 2022Article
- Cyclodextrin Inclusion Complexes with Antibiotics and Antibacterial Agents as Drug-Delivery Systems-A Pharmaceutical Perspective.Pharmaceutics · 2022Review
- Exploring In Vitro Biological Cellular Responses of Pegylated β-Cyclodextrins.Molecules (Basel, Switzerland) · 2022Article
- The Systems of Naringenin with Solubilizers Expand Its Capability to Prevent Neurodegenerative Diseases.International journal of molecular sciences · 2022Article
- Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability.Pharmaceutics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We herein disclose how global cyclodextrin-based pharmaceutical technologies have evolved since the early 80s through a 1998 patents dataset retrieved from Derwent Innovation Index. We used text-mining techniques based on the patents semantic content to extract the knowledge contained therein, to analyze technologies related to the principal attributes of CDs: solubility, stability, and taste-masking enhancement. The majority of CDs pharmaceutical technologies are directed toward parenteral aqueous solutions. The development of oral and ocular formulations is rapidly growing, while technologies for nasal and pulmonary routes are emerging and seem to be promising. Formulations for topical, transdermal, vaginal, and rectal routes do not account for a high number of patents, but they may be hiding a great potential, representing opportunity research areas. Certainly, the progress in materials sciences, supramolecular chemistry, and nanotechnology, will influence the trend of that, apparently neglected, research. The bottom line, CDs pharmaceutical technologies are still increasing, and this trend is expected to continue in the coming years. Patent monitoring allows the identification of relevant technologies and trends to prioritize research, development, and investment in both, academia and industry. We expect the scope of this approach to be applied in the pharmaceutical field beyond CDs technological applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.